Home > Journals > Minerva Cardioangiologica > Past Issues > Articles online first > Minerva Cardioangiologica 2020 Feb 20



To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Cardioangiologica 2020 Feb 20

DOI: 10.23736/S0026-4725.20.05078-1


language: English

Glifozines and cardio-renal outcomes

Luca DI LULLO 1 , Antonio BELLASI 2, Edoardo GUASTAMACCHIA 3, Vincenzo TRIGGIANI 3, Claudio RONCO 4, Carlo LAVALLE 5, Biagio R. DI IORIO 6, Domenico RUSSO 7, Giuseppe CIANCIOLO 8, Gaetano LA MANNA 8, Silvio SETTEMBRINI 9

1 Department of Nephrology and Dialysis, L. Parodi, Delfino Hospital, Colleferro, Roma, Italy; 2 Department of Research, Innovation, Brand Reputation, Bergamo Hospital, ASST Papa Giovanni XXIII, Bergamo, Italy; 3 Interdisciplinar Department of Medicine, University of Bari, Bari, Italy; 4 International Renal Research Institute, S. Bortolo Hospital, Vicenza, Italy; 5 Department of Cardiovascular Disease, Policlinico Umberto I Hospital, Rome, Italy; 6 Department of Nephrology and Dialysis, "Antonio Cardarelli" Hospital, Naples, Italy; 7 Department of Public Health, University of Naples Federico II, Naples, Italy; 8 Unit of Nephrology, Dialysis and Transplantation, Department of Experimental Diagnostic and Specialty Medicine, S.Orsola Malpighi Hospital, University of Bologna, Bologna, Italy; 9 Department of Diabetology and Metabolic Disease, Pellegrini Hospital, Naples, Italy


Diabetes mellitus, with its complications, is one of the major health problems in economically developed countries and its prevalence is constantly increasing. Kidneys and heart involvement represent main comorbidities in diabetic patients often leading to organ’s failure. The treatments available until a few years ago are often associated with hypoglycemia, weight gain, gastro-intestinal disorders and other side effects together with serious averse effects on renal function. The new frontiers of diabetic cardionephropathy treatment are mainly focused on delay of heart and renal failure both on diabetic and non - diabetic patients ad it was shown by last data reports. In the following review, we’ll focus on Gliflozins, one of the newest classes of hypoglycemic drugs that have shown to hold peculiar pharmacological properties in managing cardiac and renal complications.

KEY WORDS: Diabetes; Heart failure; Chronic renal disease; Gliflozins

top of page